BPC-157 Dosage: Medical Protocols for 2026

BPC-157 dosage is not a single number. It varies by administration route, body weight, therapeutic goal, and whether a physician has reviewed baseline biomarkers. The peptide itself remains investigational. No regulatory authority has approved it for human use. Every protocol discussed here reflects patterns observed in published research, not clinical guidelines. Physicians who prescribe BPC-157 do so off-label, after examining the individual and deciding whether the intervention is appropriate.

How Dosage Is Calculated

Body weight is the first variable. Most research-based protocols express dose in micrograms per kilogram.

A 70 kg person receives a different absolute dose than an 85 kg person, even when both follow the same microgram-per-kilogram protocol. The physician calculates the total daily amount in micrograms, then divides that by the concentration of the reconstituted vial to determine injection volume.

Key factors that influence the final number:

• Body weight in kilograms
• Route of administration (subcutaneous, intramuscular, or oral)
• Therapeutic goal (soft tissue repair, gastric protection, or systemic inflammation)
• Baseline inflammatory markers and injury severity
• Concurrent therapies

The concentration of the vial also matters. A 5 mg vial reconstituted with 2 ml of bacteriostatic water yields 2,500 mcg per ml. A 10 mg vial in the same volume yields 5,000 mcg per ml. The injection volume changes, not the absolute micrograms delivered.

Reconstitution and Concentration

Lyophilized BPC-157 arrives as a powder. The physician or pharmacist adds bacteriostatic water to create a solution. The volume of diluent determines the concentration.

Vial Size	Diluent Volume	Concentration	250 mcg Dose	500 mcg Dose
5 mg	2 ml	2,500 mcg/ml	0.10 ml	0.20 ml
10 mg	2 ml	5,000 mcg/ml	0.05 ml	0.10 ml
5 mg	5 ml	1,000 mcg/ml	0.25 ml	0.50 ml

A higher concentration means smaller injection volumes. A lower concentration spreads the same dose across more fluid. Neither changes the absolute micrograms. The physician chooses based on injection site tolerance and how many doses the vial must provide.

Storage begins the moment reconstitution is complete. Refrigeration at 2 to 8 degrees Celsius is standard. Most reconstituted vials remain stable for 28 days. After that, potency degrades.

Route-Specific Protocols

Subcutaneous injection is the most common route. The needle enters the fatty tissue below the skin, typically in the abdomen or thigh. Absorption is slower than intramuscular but more predictable than oral.

Intramuscular injection delivers the peptide into muscle tissue. The physician may recommend this route when the injury is localized in a joint or muscle belly. The injection site is usually within two inches of the affected area, though systemic circulation still occurs.

Oral capsules bypass injection entirely. Gastric acid degrades some peptide content, so the effective dose is lower than the nominal dose. Protocols for oral BPC-157 typically use higher milligram amounts to account for reduced bioavailability.

Subcutaneous vs. Intramuscular

Each route has a different onset and duration profile. Subcutaneous administration produces slower, more stable plasma levels. Intramuscular injection reaches peak concentration faster but may cause more discomfort at the site.

The physician selects the route based on the injury location and the patient's tolerance. A rotator cuff strain may justify intramuscular delivery near the shoulder. Inflammatory bowel symptoms may call for subcutaneous injection in the abdomen.

Practical differences:

• Subcutaneous: slower absorption, broader systemic distribution, minimal site pain
• Intramuscular: faster peak concentration, higher local tissue exposure, moderate discomfort
• Oral: easiest administration, lowest bioavailability, highest nominal dose required

Frequency also varies. Most subcutaneous and intramuscular protocols call for once or twice daily administration. Oral capsules may be taken two or three times daily to maintain steady gastric exposure.

Therapeutic Goal and Timing

Soft tissue repair is the most cited indication in preclinical studies. Tendon, ligament, and muscle injuries show accelerated healing in rodent models. Human data remains limited to case reports and small observational series.

Gastric protection is another studied application. A 2021 pilot study in inflammatory bowel disease reported symptom improvement in a small cohort. The dose used in that trial was weight-adjusted and delivered subcutaneously.

Timing matters. Acute injuries are typically addressed with a four to six week cycle. Chronic inflammation may justify longer protocols, but the physician must review inflammatory biomarkers at intervals to assess response and adjust the dose.

Cycle Length and Re-Assessment

Most physicians structure BPC-157 therapy in cycles, not continuous administration. A typical cycle runs four to six weeks, followed by a pause and a re-evaluation of symptoms and biomarkers.

If inflammatory markers such as C-reactive protein or erythrocyte sedimentation rate have normalized, the physician may discontinue the peptide. If symptoms persist and labs remain elevated, a second cycle may be considered.

Longer cycles carry unknown risk. BPC-157 has no long-term safety data in humans. Physicians who extend protocols beyond eight weeks do so with informed consent and regular monitoring.

Healthi Life's peptide therapy protocols begin with a physician consultation and biomarker review. Every peptide prescription, including BPC-157, follows the same sequence: measure baseline, decide on indication, administer under supervision, and re-test at intervals.

What Supervision Means in Practice

A physician-supervised protocol is not the same as buying peptides online and following a forum post. Supervision means baseline labs, a medical history review, contraindication screening, and a written treatment plan.

The physician orders inflammatory markers, complete blood count, liver and kidney function tests, and any imaging relevant to the injury. BPC-157 is prescribed only if labs suggest inflammation and if no contraindication is present.

Steps in a supervised protocol:

1. Initial consultation and history review
2. Baseline biomarker panel and imaging if indicated
3. Prescription written with dose, route, and cycle length
4. Reconstitution and first injection demonstration
5. Mid-cycle check-in (week two or three)
6. End-of-cycle re-testing and outcome review
7. Decision to continue, adjust, or discontinue

The physician adjusts dose based on response. If symptoms improve rapidly, the dose may be reduced. If no change occurs by week three, the physician may increase the dose or switch the route.

Contraindications and Monitoring

Not every patient is a candidate. Active cancer, uncontrolled infection, and pregnancy are absolute contraindications. Liver or kidney impairment may require dose adjustment or disqualification.

Monitoring continues throughout the cycle. The physician reviews symptoms at weekly or biweekly intervals. Labs are repeated at cycle end to confirm that inflammatory markers have improved and that liver and kidney function remain stable.

Adverse effects are rare in published reports, but they can occur. Injection site reactions, transient flushing, and mild headache have been noted. Any persistent symptom triggers a dose adjustment or discontinuation.

Dosage Variability Across Studies

Published human research on BPC-157 is sparse. Most dosing information comes from preclinical rodent studies, which use doses scaled to human equivalents through body surface area conversion.

Human equivalent doses derived from animal studies often land in the range of 200 to 800 micrograms per day for a 70 kg adult. The 2021 inflammatory bowel disease pilot used a similar range, adjusted for body weight.

No randomized controlled trial has established an optimal bpc-157 dosage for any indication. Physicians who prescribe it rely on observed patterns and clinical judgment.

Body Weight Adjustment Tables

Weight-adjusted dosing reduces variability between individuals. A standardized microgram-per-kilogram protocol ensures that a 60 kg person and a 90 kg person receive proportional exposure.

Body Weight (kg)	Low Dose (mcg/day)	Mid Dose (mcg/day)	High Dose (mcg/day)
60	180	300	480
70	210	350	560
80	240	400	640
90	270	450	720

These figures represent observed ranges in published protocols, not prescribing instructions. The physician selects the point within the range based on injury severity, baseline inflammation, and patient tolerance.

Injection Technique and Site Selection

Subcutaneous injections target the abdominal fat pad or the lateral thigh. The needle enters at a 45 to 90 degree angle, depending on subcutaneous tissue depth.

Intramuscular injections use a longer needle and a 90 degree angle. Common sites include the deltoid, vastus lateralis, and ventrogluteal muscles. When the goal is localized tissue repair, the physician may inject within proximity of the injury, though systemic circulation still carries the peptide throughout the body.

Technique checklist:

• Cleanse the injection site with alcohol
• Allow the skin to dry completely
• Pinch the skin for subcutaneous, or stretch it taut for intramuscular
• Insert the needle at the appropriate angle
• Aspirate (for intramuscular only) to confirm no blood return
• Inject slowly over five to ten seconds
• Withdraw the needle and apply gentle pressure

Rotation of injection sites reduces tissue irritation. A patient using once-daily subcutaneous administration should alternate between left and right abdomen, or between abdomen and thigh, each day.

Oral Capsule Protocols

Oral BPC-157 avoids needles but introduces bioavailability variability. Gastric acid and digestive enzymes degrade peptide bonds. The fraction that reaches systemic circulation is lower than with injection.

Oral dosing protocols typically start at higher nominal doses to compensate. Capsules may contain 500 to 1,000 micrograms per dose, taken twice daily.

Enteric coating can improve stability. The capsule resists gastric acid and releases its contents in the small intestine, where pH is higher and peptidases are less active. Even with enteric coating, bioavailability remains lower than parenteral routes.

Timing Relative to Meals

Some protocols recommend taking oral BPC-157 on an empty stomach to maximize absorption. Others suggest taking it with a small amount of fat to slow gastric emptying and extend exposure time.

No clinical trial has compared fed versus fasted administration. The physician makes a recommendation based on the patient's gastric tolerance and therapeutic goal.

Frequently Asked Questions

Who decides the appropriate bpc-157 dosage for my injury?
A licensed physician reviews your injury history, baseline inflammatory markers, imaging if indicated, and medical contraindications. The dose is calculated based on your body weight and therapeutic goal. No peptide is dispensed without a written prescription and a signed treatment plan.

How long does a typical cycle last?
Most cycles run four to six weeks. The physician orders mid-cycle and end-of-cycle biomarker panels to assess response. If inflammatory markers normalize and symptoms resolve, the peptide is discontinued. If no improvement occurs, the physician may adjust the dose, switch the route, or discontinue therapy.

Can I adjust my dose based on how I feel?
No. Dose adjustments are made by the prescribing physician after reviewing lab results and symptom changes. Increasing the dose without medical review raises the risk of adverse effects and provides no guarantee of better outcomes. Decreasing the dose without consultation may result in subtherapeutic exposure.

What happens if I miss a dose?
Take the next scheduled dose at the usual time. Do not double the dose to compensate. If you miss more than two consecutive doses, contact the prescribing physician to discuss whether the cycle should be restarted or discontinued.

Storage and Handling

Lyophilized powder is stable at room temperature for short periods but should be refrigerated or frozen for long-term storage. Reconstituted solution must be refrigerated at 2 to 8 degrees Celsius and used within 28 days.

Exposure to light degrades peptides. Vials should be stored in their original packaging or wrapped in foil. Freezing reconstituted BPC-157 is not recommended, as freeze-thaw cycles damage peptide structure.

Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth. Sterile water lacks this preservative and shortens the usable life of the reconstituted solution to 48 hours.

Travel and Temperature Excursions

Traveling with reconstituted BPC-157 requires a cooler with ice packs. Temperature excursions above 8 degrees Celsius for more than a few hours reduce potency.

Airport security regulations permit medically necessary injectables in carry-on luggage. A prescription letter from the physician may be required. The vial, syringes, and alcohol wipes should be packed in a clear plastic bag.

If refrigeration is unavailable during travel, the physician may pause the cycle rather than risk degraded product. Restarting after the trip is safer than continuing with subpotent peptide.

Integration with Other Therapies

BPC-157 is rarely used in isolation. Physicians combine it with physical therapy, anti-inflammatory protocols, and other regenerative therapies such as platelet-rich plasma or exosome therapy.

The sequence matters. Some physicians prefer to initiate BPC-157 first and add adjunctive therapies after two weeks. Others start all therapies concurrently and monitor for synergistic effects.

Common combinations:

• BPC-157 with physical therapy for tendon or ligament injuries
• BPC-157 with oral anti-inflammatories for acute musculoskeletal pain
• BPC-157 with exosome therapy for chronic joint degeneration
• BPC-157 with gastric mucosal protectants for inflammatory bowel symptoms

Drug interactions are not well studied. Nonsteroidal anti-inflammatory drugs (NSAIDs) are often continued during BPC-157 therapy, but the physician may reduce the NSAID dose if symptoms improve rapidly.

What Patients Report

Symptom diaries are standard in physician-supervised protocols. The patient records pain level, range of motion, digestive symptoms, and any adverse effects daily.

Most patients report gradual improvement over the first three weeks. Acute injuries may show faster response than chronic conditions. Some patients report no change, and the physician discontinues therapy after reviewing mid-cycle labs.

Patient-reported outcomes are subjective. The physician pairs them with objective measures such as inflammatory markers, imaging, and physical examination findings to decide whether to continue.

When No Improvement Occurs

Not every patient responds. Baseline inflammatory markers predict response better than symptom severity alone. A patient with low C-reactive protein and minimal tissue damage on imaging is less likely to benefit than one with elevated markers and visible pathology.

If no improvement occurs by week three, the physician reviews the dose, the route, and the diagnostic accuracy. Sometimes the injury is not inflammatory in nature, and BPC-157 is the wrong tool.

Switching from subcutaneous to intramuscular, or increasing the dose by 25 percent, may be tried before discontinuation. If the second adjustment fails, the peptide is stopped.

Reconstitution Errors and Their Consequences

Incorrect diluent volume changes the concentration. A patient who adds 5 ml instead of 2 ml to a 5 mg vial creates a 1,000 mcg/ml solution instead of 2,500 mcg/ml. If they inject the same volume, they receive less than half the intended dose.

Common errors:

• Using sterile water instead of bacteriostatic water (shortens shelf life)
• Adding too much or too little diluent (wrong concentration)
• Shaking the vial instead of gently swirling (denatures peptide)
• Failing to refrigerate after reconstitution (rapid degradation)

The physician or a trained nurse demonstrates reconstitution during the first visit. Many clinics provide pre-filled syringes to eliminate calculation errors, though this increases cost.

Legal and Regulatory Status

BPC-157 is not approved by the United States Food and Drug Administration, the European Medicines Agency, or the Thai Food and Drug Administration. It is classified as a research chemical in most jurisdictions.

Physicians in Thailand may prescribe unapproved therapies under the principle of informed consent, provided they document medical necessity and obtain written acknowledgment of off-label use from the patient.

Purchasing BPC-157 from online vendors without a prescription is legal in some countries but carries quality and safety risks. No regulatory body verifies the purity or sterility of these products.

Healthi Life sources peptides from licensed pharmaceutical suppliers who provide certificates of analysis. Every batch is tested for purity, endotoxin level, and sterility before use.

---

BPC-157 dosage is a physician-led calculation, not a forum recommendation or a product label instruction. The number depends on body weight, route, therapeutic goal, and baseline biomarkers. Every protocol begins with measurement, continues with supervision, and adjusts based on re-testing. Healthi Life offers physician-supervised peptide protocols as part of its recovery and performance medicine service in Ekkamai, Bangkok. Every prescription follows a consultation, a biomarker review, and a written treatment plan. This page is for information only and is not medical advice. Medical consultation and prescription are available online and on site at Healthi Life, Ekkamai, Bangkok.